For all the updated information regarding Covid-19 click here.   For my latest media as Prime Minister click here.

Cheaper Medicine For Over 500,000 Patients

Cheaper medicines have been delivered to more than 500,000 patients, with price reductions for common scripts and new medicines added to the Pharmaceutical Benefits Scheme (PBS), in some cases saving over $100,000 per patient.

 

Medicines to treat lung cancer, lymphoblastic and acute leukaemia, and nausea associated with chemotherapy is now  available to patients on the PBS for just $40.30 per script, or $6.50 with a concession card.

 

A further $390 million in mandated price reductions across 175 medicine brands will also flow through to patients, making medicines more affordable.

 

The new or extending PBS listings from tomorrow include:

 

Tecentriq® and Avastin®, will be extended on the PBS to include first line treatment of patients with stage IV metastatic non-squamous non-small cell lung cancer. Without PBS subsidy it would cost patients more than $11,400 per script (around 16 scripts per course of treatment); or more than $189,100 per course of treatment. An average of 755 patients per year (for six years) could benefit from this listing.

 

Besponsa®, will be extended on the PBS to include patients with relapsed or refractory Philadelphia chromosome positive B-ALL. Without PBS subsidy, patients would pay more than $44,500 per script (around 3 scripts per course of treatment); or more than $122,900 per course of treatment without subsidised access through the PBS. An average of 16 patients per year (for six years) could benefit from this listing. 

 

Blincyto®, will be extended on the PBS to include patients with relapsed or refractory Philadelphia chromosome positive B-ALL. Without PBS subsidy, patients would pay more than more than $74,900 per script (around 2 scripts per course of treatment); or more than $122,900 per course of treatment. An average of 16 patients per year (for six years) could benefit from this listing.

 

Aprepitant Apotex®, will be made available through the PBS for the treatment of patients with Nausea and vomiting associated with chemotherapy. Without PBS subsidy, patients would pay more than $80 per script (around 1 script per course of treatment). In 2018, 7,269 patients accessed a comparable treatment for this condition.

 

From 1 January 2020 the threshold to receive free or further discounted medicines through the PBS will be lowered by 12 scripts for pensioners and concession card holders and the equivalent of 2 scripts for non-concession card holders.